Accendra Health, Inc. (ACH) Guidance & Earnings Results
On 2026-08-10 Accendra Health, Inc. lowered guidance: "FY2026 revenue $2.45B-$2.55B, adjusted EBITDA $300M-$320M, free cash flow breakeven to slightly…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACHAccendra Health, Inc.Follow ACH — free
—
Price chart with a free account
- Market cap
- 16.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 10 Aug 26 | Lowered | FY2026 revenue $2.45B-$2.55B, adjusted EBITDA $300M-$320M, free cash flow breakeven to slightly positive · full year |
| 19 Feb 26 | Reaffirmed | FY2026 revenue $2.55B-$2.65B; Adj. EBITDA $335M-$355M; FCF $90M-$110M · full year |
| 30 Oct 25 | Reaffirmed | Revenue $2.76B-$2.82B, Adjusted EPS $1.02-$1.07, Adjusted EBITDA $376M-$382M · full year |
Accendra Health, Inc. — questions
- What guidance did Accendra Health, Inc. give?
- On 2026-08-10: "FY2026 revenue $2.45B-$2.55B, adjusted EBITDA $300M-$320M, free cash flow breakeven to slightly positive"
- When does Accendra Health, Inc. report earnings?
- Accendra Health, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Accendra Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.